JP2013540713A5 - - Google Patents

Download PDF

Info

Publication number
JP2013540713A5
JP2013540713A5 JP2013526475A JP2013526475A JP2013540713A5 JP 2013540713 A5 JP2013540713 A5 JP 2013540713A5 JP 2013526475 A JP2013526475 A JP 2013526475A JP 2013526475 A JP2013526475 A JP 2013526475A JP 2013540713 A5 JP2013540713 A5 JP 2013540713A5
Authority
JP
Japan
Prior art keywords
group
chal
alkyl
compound
hydrocarbon group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013526475A
Other languages
English (en)
Japanese (ja)
Other versions
JP6082347B2 (ja
JP2013540713A (ja
Filing date
Publication date
Priority claimed from GBGB1014633.0A external-priority patent/GB201014633D0/en
Application filed filed Critical
Publication of JP2013540713A publication Critical patent/JP2013540713A/ja
Publication of JP2013540713A5 publication Critical patent/JP2013540713A5/ja
Application granted granted Critical
Publication of JP6082347B2 publication Critical patent/JP6082347B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013526475A 2010-09-02 2011-09-01 ポリ不飽和長鎖ケトンを用いるリウマチ性関節炎の治療 Expired - Fee Related JP6082347B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1014633.0 2010-09-02
GBGB1014633.0A GB201014633D0 (en) 2010-09-02 2010-09-02 Rheumatoid arthritis treatment
PCT/EP2011/065123 WO2012028688A1 (en) 2010-09-02 2011-09-01 Rheumatoid arthritis treatment using polyunsaturated long chain ketones

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016216524A Division JP2017075148A (ja) 2010-09-02 2016-11-04 ポリ不飽和長鎖ケトンを用いるリウマチ性関節炎の治療

Publications (3)

Publication Number Publication Date
JP2013540713A JP2013540713A (ja) 2013-11-07
JP2013540713A5 true JP2013540713A5 (enExample) 2016-05-12
JP6082347B2 JP6082347B2 (ja) 2017-02-15

Family

ID=43013608

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013526475A Expired - Fee Related JP6082347B2 (ja) 2010-09-02 2011-09-01 ポリ不飽和長鎖ケトンを用いるリウマチ性関節炎の治療
JP2016216524A Withdrawn JP2017075148A (ja) 2010-09-02 2016-11-04 ポリ不飽和長鎖ケトンを用いるリウマチ性関節炎の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016216524A Withdrawn JP2017075148A (ja) 2010-09-02 2016-11-04 ポリ不飽和長鎖ケトンを用いるリウマチ性関節炎の治療

Country Status (10)

Country Link
US (1) US9682930B2 (enExample)
EP (1) EP2611432A1 (enExample)
JP (2) JP6082347B2 (enExample)
KR (1) KR20130112880A (enExample)
CN (2) CN109893518A (enExample)
AU (1) AU2011298340B2 (enExample)
CA (1) CA2810102A1 (enExample)
GB (1) GB201014633D0 (enExample)
IL (1) IL224963A (enExample)
WO (1) WO2012028688A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
AU2011232408B2 (en) 2010-03-24 2015-07-30 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
GB201205394D0 (en) 2012-03-27 2012-05-09 Adlens Ltd Improvements in or relating to deformable non-round membrane assemblies
GB201221329D0 (en) 2012-11-27 2013-01-09 Avexxin As Dermatitis treatment
GB201313238D0 (en) 2013-07-24 2013-09-04 Avexxin As Process for the preparation of a polyunsaturated ketone compound
GB201409363D0 (en) * 2014-05-27 2014-07-09 Avexxin As Skin cancer treatment
GB201501144D0 (en) 2015-01-23 2015-03-11 Avexxin As Process for the preparation of a polyunsaturated ketone compound
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11351127B2 (en) 2016-09-21 2022-06-07 Avexxin As Pharmaceutical composition
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
CN110996931B (zh) * 2017-06-16 2023-12-15 埃维克辛公司 用于治疗纤维化疾病的组合物和方法
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
WO2020178695A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
GB201910644D0 (en) 2019-07-25 2019-09-11 Coegin Pharma As Cancer Treatment
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US20210311022A1 (en) * 2020-03-27 2021-10-07 Organogenesis, Inc. Methods, kits and compositions for characterizing an anti-inflammatory response of a product
JP2024512060A (ja) * 2021-03-23 2024-03-18 オルガノジェネシス,インコーポレーテッド 生産物の抗炎症反応を特徴づけるための方法、キットおよび組成物
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
EP4658242A1 (en) 2023-02-03 2025-12-10 Tris Pharma, Inc. Low sodium oxybate once nightly composition

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670465A (en) * 1986-05-21 1987-06-02 Syntex (U.S.A.) Inc. Arachidonic acid analogs
JPH0987176A (ja) 1995-09-26 1997-03-31 Shiseido Co Ltd 糸球体腎炎抑制剤
JPH09268153A (ja) 1996-04-02 1997-10-14 Sagami Chem Res Center トリフルオロメチルケトン誘導体及びホスホリパーゼa2阻害剤
WO1997038688A1 (en) * 1996-04-12 1997-10-23 Peptide Technology Pty. Limited Methods of treating immunopathologies using polyunsaturated fattyacids
WO1999015129A2 (en) 1997-09-23 1999-04-01 Bristol-Myers Squibb Company SELECTIVE cPLA2 INHIBITORS
US6107334A (en) 1998-02-23 2000-08-22 Wake Forest University Dietary control of arachidonic acid metabolism
US7605149B1 (en) 1998-07-13 2009-10-20 University Of South Florida Modulation of the phospholipase A2 pathway as a therapeutic
US6031014A (en) 1998-12-08 2000-02-29 Crivello; James V. Initiator compositions and methods for their synthesis and use
JP2003505372A (ja) * 1999-07-19 2003-02-12 イーライ・リリー・アンド・カンパニー sPLA2インヒビター
US20020165119A1 (en) * 2001-01-31 2002-11-07 Alan Leff Method of treating inflammatory conditions by inhibiting cytosolic phospholipase A2
EP1243524A3 (en) 2001-03-16 2004-04-07 Pfizer Products Inc. Pharmaceutical kit for oxygen-sensitive drugs
US7101875B2 (en) * 2001-12-03 2006-09-05 Wyeth Methods for treating arthritic disorders
GB0202002D0 (en) 2002-01-29 2002-03-13 Leiv Eiriksson Nyotek A S Use
MY131170A (en) 2002-03-28 2007-07-31 Nissan Chemical Ind Ltd Therapeutic agent for glomerular disease
US20040111957A1 (en) 2002-12-13 2004-06-17 Filippini Brian B. Water blended fuel composition
WO2006106438A2 (en) * 2005-01-11 2006-10-12 Evolva Sa Modulators of ppar activity
US20060246115A1 (en) * 2005-03-04 2006-11-02 Ricardo Rueda Nutritional products for ameliorating symptoms of rheumatoid arthritis
NZ552238A (en) 2006-12-20 2009-07-31 Seperex Nutritionals Ltd An extract
WO2008075366A2 (en) 2006-12-20 2008-06-26 Medwell Laboratories Ltd. Novel conjugates of polyunsaturated fatty acids with amines and therapeutic uses thereof
WO2009038671A2 (en) * 2007-09-14 2009-03-26 Resolvyx Pharmaceuticals, Inc. Oxylipin compounds for treating autoimmune diseases
EP2217224B1 (en) 2007-11-09 2019-05-08 Basf As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
US8211947B2 (en) * 2008-01-28 2012-07-03 Guillermo Selman-Housein Sosa Composition and method for treating and preventing musculoskeletal and connective tissue disorders
EP2147910A1 (en) 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
HRP20190732T1 (hr) * 2009-05-08 2019-06-14 Basf As Polinezasićene masne kiseline za liječenje bolesti povezanih s kardiovaskularnim, metaboličkim i upalnim područjima bolesti
GB0909643D0 (en) * 2009-06-04 2009-07-22 Avexxin As Glomerulonephritis treatment
WO2011097276A1 (en) * 2010-02-02 2011-08-11 Martek Biosciences Corporation Methods and compositions for treating arthritis with docosahexaenoic acid

Similar Documents

Publication Publication Date Title
JP2013540713A5 (enExample)
JP2016503797A5 (enExample)
JP2013507423A5 (enExample)
JP2014508753A5 (enExample)
JP2008195730A5 (enExample)
WO2008064321A3 (en) Methods of treating chronic inflammatory diseases using a gm-csf antagonist
EA201490552A1 (ru) Холиновая соль замещенного циклобутендиона, обладающая противовоспалительной способностью
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
MA32812B1 (fr) Composition pharmaceutique d'un inhibiteur puissant du vhc pour une administration orale
JP2014511891A5 (enExample)
JP2016516020A5 (enExample)
JP2012092103A5 (enExample)
JP2013519675A5 (enExample)
EP1857457A3 (en) Benzimidazole derivative and its use as AII receptor antagonist
EA200601897A1 (ru) Производные тетрагидронафтиридина, пригодные в качестве лигандов рецептора н3 гистамина
JP2015537020A5 (enExample)
JP2016505614A5 (enExample)
JP2015505296A5 (enExample)
JP2016040288A5 (enExample)
EA201390917A1 (ru) Дигетероарильные соединения в качестве ингибиторов vps34
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
JP2010155827A5 (enExample)
JP2015504081A5 (enExample)
JP2015521156A5 (enExample)